Lytix Biopharma Future Growth
Future criteria checks 2/6
Lytix Biopharma is forecast to grow revenue at 120.9% per annum.
Key information
n/a
Earnings growth rate
n/a
EPS growth rate
| Biotechs earnings growth | 35.0% |
| Revenue growth rate | 120.9% |
| Future return on equity | n/a |
| Analyst coverage | Low |
| Last updated | 29 Aug 2024 |
Recent future growth updates
No updates
Recent updates
Earnings and Revenue Growth Forecasts
| Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
|---|---|---|---|---|---|
| 12/31/2026 | 232 | N/A | N/A | 213 | 1 |
| 12/31/2025 | 23 | N/A | N/A | -33 | 1 |
| 12/31/2024 | 6 | N/A | N/A | -75 | 1 |
| 6/30/2024 | 14 | -76 | -87 | -87 | N/A |
| 3/31/2024 | 15 | -86 | -101 | -101 | N/A |
| 12/31/2023 | 4 | -88 | -96 | -96 | N/A |
| 9/30/2023 | 14 | -99 | -95 | -95 | N/A |
| 6/30/2023 | 11 | -91 | -78 | -78 | N/A |
| 3/31/2023 | 11 | -61 | -55 | -55 | N/A |
| 12/31/2022 | 11 | -56 | -53 | -53 | N/A |
| 9/30/2022 | 8 | -43 | -38 | -38 | N/A |
| 6/30/2022 | 3 | -51 | 106 | 106 | N/A |
| 3/31/2022 | 4 | -63 | -56 | -56 | N/A |
| 12/31/2021 | 19 | -48 | -45 | -45 | N/A |
| 9/30/2021 | 4 | -44 | -39 | -39 | N/A |
| 6/30/2021 | 7 | -40 | -185 | -185 | N/A |
| 3/31/2021 | 6 | -35 | -25 | -25 | N/A |
| 12/31/2020 | 4 | -42 | -24 | -24 | N/A |
| 12/31/2019 | 6 | -33 | -37 | -37 | N/A |
| 12/31/2018 | 12 | -62 | -73 | -73 | N/A |
| 12/31/2017 | 14 | -69 | N/A | -70 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: Insufficient data to determine if 6BG's forecast earnings growth is above the savings rate (0.8%).
Earnings vs Market: Insufficient data to determine if 6BG's earnings are forecast to grow faster than the German market
High Growth Earnings: Insufficient data to determine if 6BG's earnings are expected to grow significantly over the next 3 years.
Revenue vs Market: 6BG's revenue (120.9% per year) is forecast to grow faster than the German market (5.4% per year).
High Growth Revenue: 6BG's revenue (120.9% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if 6BG's Return on Equity is forecast to be high in 3 years time